Trump DROPS HAMMER: Funding Axed

Stack of coins labeled funding with other coins stacks

Trump’s move to cut millions in taxpayer funding from Springer Nature over COVID cover-up allegations blasts open the latest front in the war on politicized science, government waste, and the subversion of American values.

At a Glance

Trump administration halts $20 million in federal contracts with Springer Nature, citing concerns over COVID-19 research integrity and political bias.
Springer Nature faces record retractions and accusations of censorship to appease China and leftist activists.
Federal agencies lose access to thousands of scientific and medical journals as part of a broader crackdown on “woke” institutions.
NIH shifts toward open-access publishing amid scrutiny of taxpayer dollars funding partisan science.

Trump Slashes Funding: No More Blank Checks for Partisan Science

The Trump administration has swung the axe on $20 million in federal contracts with Springer Nature, the academic publishing behemoth, effectively telling the world’s largest scientific publisher to find another sugar daddy. This, folks, is what happens when you take taxpayer money, then serve up a heaping side of political bias, censorship, and a refusal to answer basic questions about COVID’s origins. Springer Nature’s record-shattering 2,923 research retractions in 2024—yes, nearly three thousand—was the final insult. The message is clear: If you’re going to play politics and cover for China instead of serving science and the American people, don’t expect endless government handouts.

For years, Springer Nature has raked in millions from U.S. agencies like the NIH, offering paywalled access to supposedly peer-reviewed research. But when the COVID-19 pandemic exploded, Springer was front and center downplaying the lab-leak theory and scrubbing content critical of China—ironically, the same regime that kicked off this global mess. And while they were at it, they bent over backward to accommodate woke activists, yanking studies on gender dysphoria and other topics that didn’t fit the day’s narrative. The Trump administration’s move isn’t just about the bottom line; it’s about restoring sanity, transparency, and accountability to an academic sector that’s become addicted to taxpayer cash and allergic to the truth.

Springer Nature: Poster Child for Censorship, Retractions, and Hypocrisy

Springer Nature didn’t get the boot for a few editorial mishaps. Let’s be honest—this is a publisher with a pattern. In 2017, they openly restricted access to hundreds of articles at China’s request, showing how quickly “science” gets sold out when there’s profit and power to be had. Fast forward to the COVID era, and the manipulation only got worse. When the world desperately needed honest answers, Springer’s flagship journals ran interference for the lab-leak deniers, while quietly retracting papers that challenged leftist orthodoxy. Nearly three thousand retractions in a single year—that’s not a “mistake,” that’s a system-wide collapse of integrity.

Springer’s silence on these terminations is deafening, but hardly surprising. When you’ve feasted on government largesse while dodging basic questions about editorial standards and foreign influence, there’s not much left to say. The fact that the NIH and cancer research agencies had to declare some subscriptions “mission essential” just to keep vital research flowing tells you everything you need to know about how dependent the scientific establishment has become on a few favored gatekeepers. Meanwhile, President Trump and congressional allies are making it clear: the days of rubber-stamping contracts for partisan science are over.

Open Access, Open Season: NIH Shifts Course as Congress Turns Up the Heat

NIH Director Jay Bhattacharya’s announcement of a new open-access policy for federally funded research marks a seismic shift. No more hiding taxpayer-funded science behind paywalls owned by publishers who play politics. Now, the public gets immediate access to the research it paid for—exactly as it should be. Congressional committees are zeroing in, investigating not just Springer, but the entire corrupt ecosystem that’s thrived on backroom deals, censorship, and the cult of “woke” orthodoxy.

Critics of Trump’s move are predictably hand-wringing about “research competitiveness” and “international collaboration.” But maybe, for once, we should worry less about keeping Springer’s shareholders happy and more about making science accountable to the American people. If Springer Nature and its ilk want to keep cashing in, maybe they should try publishing research that stands up to scrutiny—without caving to foreign dictators or activist mobs. Until then, the American taxpayer has every right to demand better.